 This is an investigational study. Pomalidomide is FDA approved and commercially available for the treatment of multiple myeloma in patients whose disease has not gotten worse within 60 days after receiving at least 2 prior therapies including lenalidomide and bortezomib.The combination of pomalidomide, dexamethasone, and filgrastim to treat MM is investigational. 